Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Letai

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Nature Cancer|May 17, 2021
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C Watt, Paloma Cejas, Molly J DeCristo, et al.
Cell Reports|December 30, 2015
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Juliana M Benito, Laura Godfrey, Kensuke Kojima, et al.
Blood Cancer Discovery|January 15, 2021
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular VulnerabilitiesRuth Flümann, Tim Rehkämper, Pascal Nieper, et al.
Nature|May 20, 2005
An inhibitor of Bcl-2 family proteins induces regression of solid tumoursTilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al.
Cancer Discovery|June 15, 2021
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient ScreeningGadi Lalazar, David Requena, Lavoisier Ramos-Espiritu, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Nature Communications|May 21, 2016
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibitionJan A Burger, Dan A Landau, Amaro Taylor-Weiner, et al.
Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Nature|February 19, 2010
The landscape of somatic copy-number alteration across human cancersRameen Beroukhim, Craig H Mermel, Dale Porter, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Nature Cancer|May 17, 2021
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C Watt, Paloma Cejas, Molly J DeCristo, et al.
Cell Reports|December 30, 2015
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Juliana M Benito, Laura Godfrey, Kensuke Kojima, et al.
Blood Cancer Discovery|January 15, 2021
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular VulnerabilitiesRuth Flümann, Tim Rehkämper, Pascal Nieper, et al.
Nature|May 20, 2005
An inhibitor of Bcl-2 family proteins induces regression of solid tumoursTilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al.
Cancer Discovery|June 15, 2021
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient ScreeningGadi Lalazar, David Requena, Lavoisier Ramos-Espiritu, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Nature Communications|May 21, 2016
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibitionJan A Burger, Dan A Landau, Amaro Taylor-Weiner, et al.
Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Nature|February 19, 2010
The landscape of somatic copy-number alteration across human cancersRameen Beroukhim, Craig H Mermel, Dale Porter, et al.
Pageof 19